Funding
SynapSense approaches funding as a mechanism to support rigorous scientific validation, not as a driver of premature deployment or exaggerated claims.
Current Funding Status
SynapSense is an early-stage, pre-revenue research initiative operating as SynapSense Technologies LLC. The project is currently supported through a combination of academic resources, program-based support, and founder-led operational contributions.
No clinical claims, diagnostic services, or commercial products are being funded or offered at this stage.
Program-Based Support and Recognition
SynapSense has been selected for participation in competitive research and founder development programs that provide structured mentorship, peer review, and non-dilutive support.
Spring 2026
Founder Program, Spring 2026
These programs provide validation, structured feedback, and institutional credibility rather than direct commercial funding.
Use of Funds
Funding and resources support the following core activities:
- Human-subject research conducted under IRB oversight
- EEG equipment usage, maintenance, and consumables
- Data storage, security, and computational infrastructure
- Participant recruitment and study logistics
- Signal processing and analysis development
- Academic dissemination and conference participation
All expenditures are aligned with research objectives and ethical requirements.
Non-Dilutive Funding Focus
SynapSense prioritizes non-dilutive funding sources at this stage to preserve scientific independence and allow adequate time for validation. These sources include:
- Academic and institutional support
- Research and innovation programs
- Grants aligned with neuroscience, pain research, and biomedical engineering
- Program-based stipends or resources
Equity-based funding is not a current priority and will only be considered following substantial additional validation.
Financial Stewardship
Financial oversight emphasizes transparency, accountability, and sustainability. Budgeting and resource allocation are managed to ensure that research activities are adequately supported without compromising ethical or methodological standards.
All funding decisions are evaluated against defined research milestones and compliance requirements.
Future Funding Considerations
Future funding efforts may be pursued to support:
- Expanded feasibility or validation studies
- Longitudinal research designs
- Increased participant diversity and sample size
- Preparation for translational or clinical feasibility research
Any future funding strategy will be contingent on demonstrated scientific reliability and alignment with SynapSense's research mission.
Research Status Statement
SynapSense remains a research-stage initiative. All funded activities are investigational and conducted under ethical oversight. Funding should not be interpreted as endorsement of clinical readiness, diagnostic capability, or regulatory approval.